Propeller Health, provider of an FDA-cleared digital health solution for improving outcomes in asthma and chronic obstructive pulmonary disease (COPD), today announced its first development and R&D collaboration agreement with GSK for development of a custom medication sensor for GSK’s Ellipta inhaler. This deal continues an accelerating trend of pharmaceutical companies working to connect respiratory medications via sensors and services to improve the use of these medications and outcomes associated with these medications.
Propeller Health, GSK R&D Collaboration Details
In the studies, the sensor will automatically collect and record data on the inhaler’s usage (i.e. date and time of each use), wirelessly transmitting the information to a central data repository for analysis by GSK’s clinical researchers. The sensor technology will be used to provide greater insights into adherence patterns across patient populations and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes.
GSK will use the Propeller sensor in upcoming clinical trials, and GSK retains an option to negotiate exclusive commercialization rights to the Propeller sensor for use with its marketed portfolio of respiratory medicines administered using the Ellipta inhaler.
The Propeller platform combines sensors, software, and care team services to improve patient outcomes by providing more insightful and efficient care. The Propeller solution has been studied in over 12 studies, totaling over 1,200 patients to date, and has demonstrated consistent improvements in asthma control, reductions in rescue inhaler use, improvements in medication adherence and prediction of oncoming exacerbations.
This is the second large pharmaceutical company to partner with Propeller Health, solidifying Propeller as the leading digital helath platform and partner of choice in respiratory medicine. In December 2013 Propeller Health announced a deal with Boehringer Ingelheim to develop a custom sensor for BI’s Respimat device.
